Emicizumab
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Severe Hemophilia A
Conditions
Severe Hemophilia A
Trial Timeline
Feb 4, 2021 → May 18, 2030
NCT ID
NCT04431726About Emicizumab
Emicizumab is a phase 3 stage product being developed by Roche for Severe Hemophilia A. The current trial status is active. This product is registered under clinical trial identifier NCT04431726. Target conditions include Severe Hemophilia A.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05181618 | Approved | Active |
| NCT04431726 | Phase 3 | Active |
| NCT04158648 | Phase 3 | Completed |
| NCT03315455 | Phase 3 | Completed |
| NCT03380780 | Phase 1 | Completed |
| NCT03191799 | Phase 3 | Completed |
Competing Products
20 competing products in Severe Hemophilia A